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Abstract
Background: Xenoestrogens and antifungal azoles probably share a common route of metabolism,
through hepatic cytochrome P450 (CYP) enzymes. Chemical interactions with metabolic pathways may
affect clearance of both xenobiotics and endobiotics. This study was carried out to identify possible
chemical interactions by those substances on CYP1A and CYP3A, in Atlantic cod liver. We investigated
effects of two xenoestrogens (nonylphenol and ethynylestradiol) and of the model imidazole ketoconazole,
alone and in combination.
Results: Treatment with ketoconazole resulted in 60% increase in CYP1A-mediated ethoxyresorufin-O-
deethylase (EROD) activity. Treatment with nonylphenol resulted in 40% reduction of CYP1A activity.
Combined exposure to ketoconazole and nonylphenol resulted in 70% induction of CYP1A activities and
93% increase in CYP1A protein levels. Ketoconazole and nonylphenol alone or in combination had no
effect on CYP3A expression, as analyzed by western blots. However, 2-dimensional (2D) gel
electrophoresis revealed the presence of two CYP3A-immunoreactive proteins, with a more basic
isoform induced by ketoconazole. Treatment with ketoconazole and nonylphenol alone resulted in 54%
and 35% reduction of the CYP3A-mediated benzyloxy-4-[trifluoromethyl]-coumarin-O-debenzyloxylase
(BFCOD) activity. Combined exposure of ketoconazole and nonylphenol resulted in 98% decrease in
CYP3A activity. This decrease was greater than the additive effect of each compound alone. In vitro studies
revealed that ketoconazole was a potent non-competitive inhibitor of both CYP1A and CYP3A activities
and that nonylphenol selectively non-competitively inhibited CYP1A activity. Treatment with
ethynylestradiol resulted in 46% decrease in CYP3A activity and 22% decrease in protein expression in
vivo. In vitro inhibition studies in liver microsomes showed that ethynylestradiol acted as a non-competitive
inhibitor of CYP1A activity and as an uncompetitive inhibitor of CYP3A activity.
Conclusions: Ketoconazole, nonylphenol and ethynylestradiol all interacted with CYP1A and CYP3A
activities and protein expression in Atlantic cod. However, mechanisms of interactions on CYP1A and
CYP3A differ between theses substances and combined exposure had different effects than exposure to
single compounds. Thus, CYP1A and CYP3A mediated clearance may be impaired in situations of mixed
exposure to those types of compounds.
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Background
A great challenge in pharmacology and toxicology is to
understand the molecular mechanisms behind how mix-
tures of compounds affect living organisms. This study
focuses on two classes of substances, imidazoles and
xenoestrogens, and how these chemicals alone and in
combination affect hepatic drug-metabolizing hepatic
cytochrome P450 (CYP) enzymes – specifically, CYP1A
and CYP3A enzymes, in juvenile Atlantic cod (Gadus
morhua).
Imidazoles and triazoles are used as fungicides both clin-
ically as well as in horticulture and agriculture, posing a
potential threat to wildlife. The triazole propiconazole has
been detected in the aquatic environment [1]. The azole
antifungal effect resides in inhibition of CYP51 mediated
ergosterol biosynthesis [2]. In addition to disrupting key
enzymes in fungus, azoles such as the imidazoles clotrim-
azole, ketoconazole, miconazole and prochloraz also
cause endocrine disruption in vertebrates by inhibition of
key enzymes in steroid homeostasis [3-7]. Moreover,
these fungicides inhibit drug-metabolizing CYP forms,
including members of the CYP1, CYP2 and CYP3 gene
families in vertebrates [5,8-13]. Effects on CYP forms may
have adverse effects on metabolic clearance of endobiotics
and xenobiotics. For example, in a study in fish, pre-expo-
sure to clotrimazole resulted in increased bioaccumula-
tion of the pro-carcinogen benzo [a]pyrene in gizzard
shad (Dorosoma cepedianum) [14].
Xenoestrogens comprise a wide variety of structurally
diverse chemicals such as o,p-DDT, ethynylestradiol,
alkylphenols and bisphenol A. These substances are well-
known or supposed to be endocrine disrupting substances
in vertebrates and share in common that they activate the
estrogen receptor (ER) and thereby elicit estrogenic
responses [15-17]. In addition to being estrogenic, these
xenoestrogens interact with drug-metabolizing CYP
forms, including members of the CYP1A and CYP3A sub-
families in vertebrates [18-22].
Xenoestrogens are continuously released into the environ-
ment as a result of various anthropogenic activities. Induc-
tion of vitellogenesis in fish is a biomarker routinely used
to assess the presence of estrogenic substances in the
aquatic environment [23,24]. Induction of CYP1A-medi-
ated ethoxyresorufin-O-deethylase (EROD) activity is
another established biomarker used to assess exposure to
aromatic hydrocarbons. This response proceeds through
activation of the aryl hydrocarbon receptor (AHR) by aro-
matic hydrocarbons including polyaromatic hydrocar-
bons, and planar polychlorinated biphenyls and dioxins
[25]. Some AHR agonists have been shown to be anti-
estrogenic and cross-talk between AHR and ER has been
suggested in vertebrates [26-33].
In addition to activation of the ER, xenoestrogens also
affect other steroid receptors. Nonylphenol up-regulated
CYP3A1 gene expression in rat, through activation of the
pregnane X receptor (PXR) [34,35]. We previously
reported induction of CYP3A and CYP1A protein levels in
Atlantic cod exposed to alkylphenols [22].
Azole fungicides induce expression of multiple vertebrate
CYP genes including members of the CYP1A, CYP2B and
CYP3A subfamilies [8,9,13,36-38]. Clotrimazole activates
the ligand-binding domain of the PXR, involved in
CYP3A signalling, in vitro from several mammalian spe-
cies and zebra fish (Danio rerio) [39]. Both imidazoles and
xenoestrogens inhibit drug-metabolizing enzymes,
including members of the CYP1A and CYP3A subfamilies
in vertebrates [8-13,18,20,22]. Thus, xenoestrogens and
imidazoles conceivably share common routes for
biotransformation. However, there is a lack of data regard-
ing effects of combined exposure of imidazoles and
xenoestrogens on these CYP forms in wildlife. Living
organisms usually are exposed to mixtures of different
classes of xenobiotics. Conceivably, exposure to mixtures
may be more of a health threat than exposure to single
compounds, as a result of interactions. Anthropogenic
compounds may enter the environment through indus-
trial activities and through the use of pharmaceuticals
[40]. Atlantic cod is an economically important species for
fishery and a growing aquaculture industry, in addition to
its ecological relevancy. Its distribution in the Northern
Atlantic and the North Sea makes it vulnerable to effluents
from on-shore and off-shore industries and from run-off
entering the waters near highly industrialized and urban-
ized areas.
The rationale of the present study was to identify possible
sites of interactions between imidazoles and xenoestro-
gens. We hypothesise that combined exposure to these
compounds may compromise the metabolic clearance
not only of these xenobiotics themselves, but also of
endobiotics such as circulating steroid hormones that
share common routes of metabolism through hepatic
CYP1A and CYP3A. Such endocrine disrupting effects may
adversely affect the stability of wildlife populations.
The specific aim of our study was to examine interactions
between two classes of compounds in livers of Atlantic
cod. Thus, we investigated the effects of the model imida-
zole ketoconazole and of two types of xenoestrogens
(nonylphenol and ethynylestradiol), as well as of a mixed
exposure to ketoconazole and nonylphenol, on hepatic
CYP1A and CYP3A protein expression and catalytic activ-
ities, and also on vitellogenesis and plasma levels of sex
steroid hormones.Comparative Hepatology 2005, 4:2 http://www.comparative-hepatology.com/content/4/1/2
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Results
In vivo effects on CYP1A
Exposure to ketoconazole (12 mg/kg b.w.) and/or a com-
bination of ketoconazole and nonylphenol (12 mg/kg
b.w. + 25 mg/kg b.w.) resulted, respectively, in 159 and
172% average induced increases in CYP1A-mediated
EROD activities (Fig. 1A), and in 133 and 193% increases
in CYP1A protein levels in Atlantic cod (Fig. 1B). Treat-
ment with nonylphenol (25 mg/kg b.w.) resulted in 41%
reduction and ethynylestradiol (5 mg/kg b.w.) resulted in
72% reduction, respectively, of CYP1A activities com-
pared to vehicle treated fish (Fig. 1A). However, when
compared to fish exposed to the combination of ketoco-
nazole and nonylphenol, exposure to nonylphenol alone
and ethynylestradiol resulted in 65% and 84% decrease in
CYP1A activity (Fig. 1A). Exposure to nonylphenol and
ethynylestradiol had no effect on CYP1A protein expres-
sion (Fig. 1B). The CYP1A protein levels were elevated by
93% in fish exposed to a mixture of ketoconazole and
nonylphenol (Fig. 1B).
In vivo effects on CYP3A
Fish exposure to ketoconazole, ethynylestradiol and non-
ylphenol resulted in decreased CYP3A-mediated benzy-
loxy-4-[trifluoromethyl]-coumarin-O-debenzyloxylase
(BFCOD) activities, when compared to vehicle treated fish
(Fig. 2A). Furthermore, mixed exposure to ketoconazole
and nonylphenol resulted in a 98% decrease in CYP3A
activity, which was greater than the additive effects of
these two compounds administrated alone (Fig. 2A). Fish
exposed to the ketoconazole and nonylphenol mixture
displayed significantly reduced CYP3A activities when
compared all other treatment groups (Fig. 2A). No effect
on CYP3A protein expression was observed in fish treated
with ketoconazole and nonylphenol, either alone or in
combination (Fig. 2B). However, ethynylestradiol treat-
ment resulted in 22% decrease in CYP3A protein levels
(Fig. 2B).
Western blot analyses of CYP3A proteins using PAb
against rainbow trout CYP3A revealed the presence of one
CYP3A immunoreactive protein band in liver micro-
somes, with an apparent molecular size above 50 kD, in
Atlantic cod (Fig. 3A). By using 2D gel electrophoresis fol-
lowed by immunoblotting, two immunoreactive CYP3A
protein spots were detected above 50 kD, with pI values
around 4.8 and 5.1, respectively (Fig. 3B). The most basic
isoprotein appears to be inducible by treatment with keto-
conazole (Fig. 3B). Ethynylestradiol and nonylphenol
treatment did not induce expression of the more basic iso-
form. Present data does not elucidate whether those two
protein spots are different gene products, or if they result
from post-translational modifications such as
phosphorylation.
In vitro inhibition studies
In vitro inhibition studies using pooled Atlantic cod liver
microsomes showed that ketoconazole, nonylphenol,
ethynylestradiol and the ketoconazole:nonylphenol (1:5)
mixture inhibited CYP1A (EROD) activity, with IC50 val-
ues (inhibitor concentration required to achieve a 50%
inhibition) ranging from 0.6 to 20 µM. The CYP3A-medi-
ated BFCOD activity also was inhibited by ketoconazole
(IC50 = 0.3 µM), ethynylestradiol (IC50 = 40 µM) and the
ketoconazole:nonylphenol (1:5) mixture (IC50  = 5:25
µM). Nonylphenol alone was an insignificant inhibitor of
microsomal CYP3A activities in Atlantic cod (IC50 = 160
µM). For comparison, IC50 values for nonylphenol and
ethynylestradiol also were determined in cDNA expressed
human CYP3A4 baculovirus supersomes, compared to
the prototypical CYP3A4 inhibitor ketoconazole (IC50 =
0.4  µM). In contrast to Atlantic cod liver microsomes,
nonylphenol inhibited the human CYP3A4 mediated
BFCOD activity (IC50 = 35 µM) and ethynylestradiol was
a weak inhibitor (IC50 = 50 µM) of this activity. The IC50
values are summarized in Table 1.
The inhibitory effects of these compounds were further
investigated on hepatic microsomal CYP1A and CYP3A
enzyme kinetics. The Ki values were determined in Dixon
plots (Figs. 4 and 5) and summarized in Table 1. Ketoco-
nazole was a potent non-competitive inhibitor of both
CYP1A and CYP3A activities with Ki values in the sub-µM
range (Fig. 4; Table 1). Ethynylestradiol was a non-com-
petitive inhibitor of CYP1A with Ki from 5.4 to 10.3 µM
and an uncompetitive inhibitor of CYP3A with Ki from 54
to 95 µM (Fig. 5; Table 1). Nonylphenol was a non-com-
petitive inhibitor of CYP1A activity with Ki around 3.5 µM
(Table 1). There were no effects of pre-incubation either
with ketoconazole or ethynylestradiol on hepatic micro-
somal CYP3A protein levels in this study (Fig. 6).
Plasma vitellogenin- and sex steroid hormone levels
Treatment with nonylphenol, ethynylestradiol and the
combination of ketoconazole and nonylphenol resulted
in induction of vitellogenin, whereas these treatments had
no statistically significant effect on 17β-estradiol, testo-
sterone and 11-keto-testosterone plasma levels compared
to either vehicle treated fish or fish treated with each test
compound alone. The results are summarized in Table 2.
Discussion
Effects on CYP1A
For data evaluation we must bear in mind that western
blot analysis of CYP1A protein levels is less sensitive than
the EROD assay [41] and so densitometry analysis of west-
ern blot data fails to detect minor changes. Treatment of
juvenile Atlantic cod with ketoconazole resulted in ele-
vated EROD activities. Mixed exposure to ketoconazole
and nonylphenol resulted in induced EROD activities andComparative Hepatology 2005, 4:2 http://www.comparative-hepatology.com/content/4/1/2
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A) In vivo CYP1A enzyme activities (A) and in vivo CYP1A protein expression (B) Figure 1
A) In vivo CYP1A enzyme activities (A) and in vivo CYP1A protein expression (B). CYP1A enzyme activities and 
protein expression in juvenile Atlantic cod exposed in vivo to vehicle (5 ml peanut oil/kg fish), ketoconazole (12 mg/kg fish), 
nonylphenol (25 mg/kg fish), ethynylestradiol (5 mg/kg fish) and ketoconazole + nonylphenol (12 + 25 mg/kg fish). A) EROD 
activities. B) CYP1A protein levels analyzed using PAb against rainbow trout CYP1A. Each bar represents mean values of eight 
to nine fish ± SD; aSignificantly different from vehicle treated fish; bSignificantly different from ketoconazole+nonylphenol 
treated fish; P < 0.05.
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In vivo CYP3A enzyme activities (A) and in vivo CYP3A protein expression (B) Figure 2
In vivo CYP3A enzyme activities (A) and in vivo CYP3A protein expression (B). CYP3A enzyme activities and pro-
tein expression in juvenile Atlantic cod exposed in vivo to vehicle (5 ml peanut oil/kg fish), ketoconazole (12 mg/kg fish), nonyl-
phenol (25 mg/kg fish), ethynylestradiol (5 mg/kg fish) and ketoconazole + nonylphenol (12 + 25 mg/kg fish). A) BFCOD 
activities. B) CYP3A protein levels analyzed using PAb against rainbow trout CYP3A. Each bar represents mean values of eight 
to nine fish ± SD; aSignificantly different from vehicle treated fish; bSignificantly different from ketoconazole+nonylphenol 
treated fish; P < 0.05.
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CYP3A Western blot (A) and CYP3A 2D-immunoblots (B) Figure 3
CYP3A Western blot (A) and CYP3A 2D-immunoblots (B). A) Western blot of hepatic microsomal CYP3A proteins 
in juvenile Atlantic cod treated with vehicle (5 ml peanut oil/kg fish) and ketoconazole (12 mg/kg fish) detected using PAb 
against rainbow trout CYP3A. B) 2D-gel electrophoresis followed by immunoblotting using PAb against rainbow trout CYP3A. 
Each blot represent pooled liver microsomes of eight to nine fish for each treatment; vehicle (5 ml peanut oil/kg fish), ketoco-
nazole (12 mg/kg fish), nonylphenol (25 mg/kg fish), ethynylestradiol (5 mg/kg fish), ketoconazole + nonylphenol (12 + 25 mg/kg 
fish).
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CYP1A protein levels. Induction of hepatic CYP1A gene
expression by exposure to imidazoles and/or triazoles also
has been reported in rat, bobwhite quail (Colinus virgin-
ianus) and rainbow trout (Oncorhynchus mykiss)
[8,13,37,38]. However, it is possible that induction of
EROD activity, partly or completely, is masked by CYP1A
inhibition caused by ketoconazole present in the tissue.
Inhibition of CYP1A is supported in the present study,
showing that ketoconazole was a potent non-competitive
inhibitor of EROD activity in vitro. Ketoconazole and
other imidazoles also have been shown to be potent
inhibitors of EROD activities in other vertebrates
[9,13,14,42].
Treatment of Atlantic cod with nonylphenol and ethy-
nylestradiol resulted in decreased EROD activities,
whereas no effects of these substances were observed on
CYP1A protein levels. This decrease in EROD activity is
probably caused by nonylphenol or ethynylestradiol
present in the liver microsome fraction. Nonetheless,
chemical data are required, in the future, to confirm this.
In vitro inhibition studies in liver microsomes confirmed
that nonylphenol and ethynylestradiol acted as non-com-
petitive inhibitors of the EROD activity. Hence, ketocona-
zole, nonylphenol, and ethynylestradiol interact with
CYP1A enzymes, indicating a possible site for interaction
of these different classes of xenobiotics. In addition, keto-
conazole treatment induces CYP1A expression, which fur-
ther may affect this interaction.
Effects on CYP3A
Atlantic cod exposed to nonylphenol, ethynylestradiol
and ketoconazole displayed reduced hepatic CYP3A
(BFCOD) activities. The CYP3A inhibitory effect by keto-
conazole is well known and ketoconazole is the most
established diagnostic inhibitor, used to assess human in
vitro CYP3A4 activity [12,43]. Studies in fish demonstrate
that ketoconazole is a potent inhibitor of hepatic BFCOD
activities in killifish (Fundulus heteroclitus), rainbow trout
and Atlantic cod with IC50 values at 0.01, 0.1 and 0.3 µM,
respectively [13,22]. In rainbow trout, exposure to ketoco-
nazole resulted in elevated hepatic and intestinal CYP3A
protein levels [13]. In the present study, 2D gel electro-
phoresis revealed the presence of two CYP3A immunore-
active spots in Atlantic cod liver microsomes with pI
values around 4.8 and 5.1, respectively. The more basic
isoform (pI 5.1) appeared to be responsive to ketocona-
zole treatment. The existence of multiple CYP3A genes has
been shown in several vertebrate species, including tele-
osts [44]. It is conceivable that there are two different
CYP3A genes in Atlantic cod and that these genes respond
differently to ketoconazole treatment. Protein isoforms
revealed on 2D gel electrophoresis may also be due to
post-translational modifications such as phosphorylation
[45]. Phosphorylation of several members of the CYP2
gene family, through phosphokinase A, resulted in imme-
diate loss in catalytic activity [46]. The shift to a more
basic form in this report could imply a dephosphorylation
of CYP3A upon ketoconazole treatment. However, as
these spots were not detected directly on the 2D gels by
using either Coomassie blue or silver staining, no spots
could be selected for sequencing to investigate whether
these two immunoreactive spots represent different gene
products.
In juvenile Atlantic salmon (Salmo salar), multiple hepatic
CYP3A proteins also were seen [19]. The two proteins
responded differently to nonylphenol treatment. High
doses of nonylphenol (125 mg/kg b.w.) suppressed the
high-molecular weight CYP3A protein band, whereas
lower doses of nonylphenol (25 mg/kg b.w.) resulted in
induction of this isoform [19]. In the present study, expo-
sure to nonylphenol resulted in reduced CYP3A activities
in juvenile Atlantic cod liver. Nevertheless, nonylphenol
did not inhibit microsomal BFCOD activities in vitro,
whereas nonylphenol was a weak inhibitor of that activity
using recombinant human CYP3A4. The Atlantic cod we
exposed to a mixture of ketoconazole and nonylphenol
Table 1: IC50 values and inhibition constants (Ki) for ketoconazole and xenoestrogens on CYP1A- and CYP3A activities assayed in 
vitro.
Compound(s) IC50(µM)1,a Ki(µM)1,a IC50(µM)2,b Ki(µM)2,b IC50(µM)3,b
Ketoconazole (KC) 0.6 (0.0)c 0.04 – low [S] 0.3 (0.1)c 0.2 0.4c
0.2 – high [S]
Nonylphenol (NP) 5.2 (1.1) 3.5 160 (40) Not analysed 35
Ethynylestradiol 20 (1.2) 5.4 – low [S] 40 (7.1) 54 – low [S] 50
10.3 – high [S] 95 – high [S]
KC:NP (1:5) 1.3 (0.2):6.2 (1.0) Not analysed 5.3 (1.1):25.0 (5.3) Not analysed Not analysed
1 Hepatic Microsomal CYP1A activity; 2 Hepatic Microsomal CYP3A activity; 3 cDNA Expressed Human CYP3A4; a Substrate [S] = 7-
Ethoxyresorufin; b [S] = 7-Benzyloxy-4-[trifluoromethyl]-coumarin; c Published in [22]. Each IC50 value represents the mean from 2–4 separate 
assays, followed by the SD, in brackets. The Ki values are estimated from one representative Dixon plot.Comparative Hepatology 2005, 4:2 http://www.comparative-hepatology.com/content/4/1/2
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Non-competitive inhibition of CYP1A by ketoconazole (A) and non-competitive inhibition of CYP3A by ketoconazole (B) Figure 4
Non-competitive inhibition of CYP1A by ketoconazole (A) and non-competitive inhibition of CYP3A by keto-
conazole (B). Dixon plots for ketoconazole on A) EROD activity (diamonds represent 8.2; squares represent 25 and triangles 
represent 677 pM ethoxyresorufin). B) BFCOD activity (diamonds represent 48; squares represent 84 and triangles represent 
200 µM BFC).
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Non-competitive inhibition of CYP1A by ethynylestradiol (A) and uncompetitive inhibition of CYP3A by ethynylestradiol (B) Figure 5
Non-competitive inhibition of CYP1A by ethynylestradiol (A) and uncompetitive inhibition of CYP3A by ethy-
nylestradiol (B). Dixon plots for ethynylestradiol on A) EROD activity (diamonds represent 8.2; squares represent 25 and 
triangles represents 677 pM ethoxyresorufin). B) BFCOD activity (diamonds represent 200; squares represent 267 and trian-
gles represents 356 µM BFC).
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displayed in vivo CYP3A activities that were lower than the
additive effect of each compound administered alone. The
mechanism for this possible interaction still is not known.
In mammals, more than one substrate can simultaneously
bind to the active site of CYP3A4 [11]. Thus, in Atlantic
cod, conceivably both ketoconazole and nonylphenol
might bind to CYP3A enzyme and prevent access of the
diagnostic BFC substrate. The CYP3A protein levels
remained unchanged in these fish suggesting that
combined exposure of ketoconazole and nonylphenol
selectively inhibits in vivo CYP3A activity.
Ethynylestradiol has been shown to act as a mechanistic
inactivator (i.e.  "suicide" substrate) of the CYP3A4
enzyme, resulting in loss of CYP3A4 protein levels
[47,48]. In Atlantic cod, a possible mechanism-based
CYP3A Western blot after in vivo incubation Figure 6
CYP3A Western blot after in vivo incubation. Western blot of CYP3A proteins in pooled liver microsomes from Atlan-
tic cod detected using PAb against rainbow trout CYP3A. The blot illustrates representative samples after in vitro incubation 
with 1.0 µM ketoconazole and 50 µM ethynylestradiol for 30 or 60 min.
Table 2: Plasma levels of vitellogenin and sex steroid hormones in juvenile Atlantic cod exposed in vivo to ketoconazole and 
xenoestrogens.
Treatment Vitellogenin 17β-Estradiol Testosterone 11-Keto-Testosterone
(µg/ml plasma) (pg/ml plasma) (pg/ml plasma) (pg/ml plasma)
n = 7–8 n = 8 n = 7–8 n = 6–8
Vehicle (5 ml peanut oil/kg b.w.) 0.6 (1.0) 62 (56) 86 (68) 33 (38)
Ketoconazole (KC) (12 mg/kg b.w.) 0.6 (0.9) 60 (26) 120 (78) 71 (46)
Nonylphenol (NP) (25 mg/kg b.w.) 266 (199) a 76 (52) 75 (33) 42 (67)
Ethynylestradiol (5 mg/kg b.w.) 4,350 (1,463) a 100 (69) 90 (40) 35 (23)
KC + NP (12 + 25 mg/kg b.w.) 268 (205) a 36 (28) 61 (51) 36 (38)
a Significantly different from vehicle treated fish (P < 0.001; Kruskal-Wallis ANOVA, followed by Mann-Whitney U-test). Each value represents the 
mean from 6–8 fish, followed by the SD, in brackets.
- +         - +         - +          - +          - +       NADPH
Ketoconazole
(1 µM)
Ketoconazole
(1 µM)
Ethynylestradiol
(50 µM)
Ethynylestradiol
(50µM)
Vehicle
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inactivation of CYP3A by ethynylestradiol was suspected.
Thus, exposure to ethynylestradiol resulted in
significantly reduced CYP3A levels and ethynylestradiol
acted as an uncompetitive inhibitor of microsomal
CYP3A activities. However, pre-incubation of hepatic
microsomes with ethynylestradiol for up to 60 min did
not result in any significant loss of CYP3A protein con-
tent, which implies that, in Atlantic cod, ethynylestradiol
is not acting as mechanism-based inhibitor of CYP3A.
Nonetheless, further studies are needed, as for example
2D gel electrophoresis of pre-incubated liver microsomes
followed by immunoblotting.
Vitellogenesis and sex steroid hormones
In humans, prolonged ketoconazole therapy results in
decreased clearance of 17β-estradiol, which may cause
gynecomastia, presumably through inhibition of hepatic
CYP3A4 [5]. In the present study, nonylphenol dependent
induction of vitellogenesis was not significantly affected
by treatment with a single dose of ketoconazole. In the
present study, exposure to xenoestrogens and ketocona-
zole alone had no statistically significant effect on sex ster-
oid levels compared to control fish. In another study in
first spawning Atlantic cod, exposure to alkylphenols
resulted in decreased plasma levels of 17β-estradiol (in
females) and testosterone and 11-keto-testosterone (in
males) [49]. Additional data, including plasma levels of
ethynylestradiol, and increasing the sample sizes are
required to definitely elucidate whether, in Atlantic cod,
exposure to xenoestrogen and ketoconazole alone or in
combination may affect sex steroid homeostasis.
Conclusions
This study identifies, in Atlantic cod, interactions between
ketoconazole and two different types of xenoestrogens on
CYP1A and CYP3A. Ketoconazole acted as a non-compet-
itive inhibitor of CYP1A and CYP3A activities and ketoco-
nazole treatment also induced CYP1A protein expression.
Ethynylestradiol acted as a non-competitive inhibitor of
CYP1A and an uncompetitive inhibitor of CYP3A activi-
ties. In vitro studies revealed that nonylphenol was a non-
competitive inhibitor of CYP1A; but it did not inhibit
CYP3A. However, in vivo, nonylphenol synergistically
impaired the ketoconazole-mediated inhibition of CYP3A
activity, without affecting CYP3A protein levels. The study
further illustrates that induction of CYP1A- and CYP3A
gene expression can be partly or completely masked by
inhibition of catalytic activities or vice versa. Taken
together, the results indicate that CYP1A and CYP3A rep-
resent sites of interactions between those classes of xeno-
biotics. In future risk-assessment of, e.g., municipal
effluents or produced water from oil platforms, that have
been shown to contain xenoestrogens, it should be con-
sidered to identify other classes of substances, for example
azoles that also interact with CYP1A and CYP3A. Our data
may warn for ecotoxicological implications, as induction
of EROD activity as well as plasma vitellogenin routinely
are used as biomarkers to assess exposure to AHR and ER
agonists in various biomonitoring programs in the
aquatic environment.
Methods
Chemicals
The 4-nonylphenol and the 17α-ethynylestradiol, for the
in vivo exposure experiment, were obtained from Fluka
Chemie AG (Buchs, Switzerland). The 4-nonylphenol for
the in vitro inhibition studies was from Berol Nobel (Ste-
nungsund, Sweden). Dimethylsulphoxide (DMSO), 7-
ethoxyresorufin, horseradish peroxidase- (HRP) conju-
gated goat-anti-mouse IgG, iodoacetamide, ketoconazole,
ponceau-S, resorufin and tween-20 were obtained from
Sigma Aldrich (Stockholm, Sweden). Reduced nicotina-
mide-adenine-dinucleotide-phosphate (NADPH) was
from Roche Diagnostics (St Louis, MO, USA and Bromma,
Sweden). Ready gels (12% continuous acrylamide in
Tris:HCl), 3-[(3-cholamidopropyl)-dimethylammonio]-
1-propanesulfonate (CHAPS), precision protein stand-
ards (low range) and supported nitrocellulose membrane
(0.45  µm) were purchased from BioRad (Sundbyberg,
Sweden). The 17β-estradiol and testosterone enzyme
immuno assay (EIA) kits were purchased from Cayman
Chemical (Ann Arbor, MI, USA). The 11-keto-testosterone
EIA kit and the Atlantic cod vitellogenin Enzyme Linked
ImmunoSorbent Assay (ELISA) kit were obtained from
Biosense Laboratories AS (Bergen, Norway). HRP-conju-
gated donkey-anti-rabbit IgG, the ECL™ Western blotting
detection reagents and Immobiline™ DryStrip 7 cm
ranging from pH 4 to 7 were from Amersham Biosciences
(Uppsala, Sweden). Ampholytes for isoelectric focusing
(Servalyt® Carrier ampholyt 3–10) was purchased from
Serva Feinbiochemica (Heidelberg, Germany). Dithioth-
reitol (DTT), Kodak X-Omat AR-ray film, X-ray developer
and fix were from VWR International (Stockholm, Swe-
den). The 7-benzyloxy-4-[trifluoromethyl] coumarin
(BFC), 7-hydroxy-4-[trifluoromethyl] coumarin (HFC)
and the CYP3A4 inhibition kit were from BD Biosciences
Company, Gentest™ (Woburn, MA, USA). All other
chemicals used were of the purest grade available in Swe-
den or Norway, from Sigma-Aldrich, BioRad and VWR
international.
Animals and sampling
Hatchery reared juvenile Atlantic cod of both sexes with
an average body weight (b.w.) around 400 g were sup-
plied by Sekkingstad, Preserving AS, Hordaland, Norway.
The fish were kept in 0.5 m3 indoor glass fibre tanks, at
Industrial Laboratory (ILAB), Bergen High Technology
Centre (Bergen, Norway), provided with continuously
flowing seawater at a temperature of 8 ± 0.5°C and a salin-
ity of 3.4%. Throughout the experimental period, the fishComparative Hepatology 2005, 4:2 http://www.comparative-hepatology.com/content/4/1/2
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were subjected to continuous 24 h artificial light (the
regime the farm used for optimal fish growth). The fish
were acclimated to these conditions for five days prior to
the experimental period. During the experimental period
the fish were starved and i.p. injected with either 12 mg
ketoconazole/kg b.w. resuspended in peanut oil (2.5 mg/
ml); 25 mg nonylphenol/kg b.w. dissolved in peanut oil
(5.0 mg/ml); 5 mg ethynylestradiol/kg b.w. dissolved in
peanut oil (1.0 mg/ml) or a mixture of ketoconazole and
nonylphenol (12 mg ketoconazole + 25 mg nonylphenol/
kg b.w. in peanut oil). Control fish were injected with 5
ml peanut oil/kg b.w. (vehicle). There were eight to nine
fish in each treatment group. When designing the
experiment, we could only test one combination due to
limited fish numbers. We selected nonylphenol to com-
bine with ketoconazole because a previous study showed
that, in Atlantic cod, alkylphenols affect CYP1A/3A more
strongly than the natural estrogen 17β-estradiol [22]. The
ketoconazole dose (12 mg/kg) was selected based on the
results on CYP1A and CYP3A protein levels and enzyme
activities from a previous dose-response study in rainbow
trout [13]. The nonylphenol dose (25 mg/kg) was selected
as this dose is known to induce vitellogenesis in a number
of fish species. In addition, in a previous study on the
Atlantic salmon, this dose of nonylphenol also had effects
on CYP1A and CYP3A [19].
After five days exposure, the fish were sacrificed by a sharp
blow to the head. Blood samples were collected from the
dorsal vein using a heparinized syringe and the liver was
quickly dissected out and placed in ice-cold homogeniza-
tion buffer (0.1 M sodium phosphate buffer pH 7.4, con-
taining 0.15 M KCl, 1 mM EDTA and 1 mM DTT). Liver
microsomes were prepared according to the published
protocol by Goksøyr [50], and stored at -80°C. Total
microsomal protein content was measured according to a
published method by Bradford [51], using bovine serum
albumin as standard, and a SpectraFluor spectrophotom-
eter from Tecan (Grödig/Salzburg, Austria). Blood plasma
was isolated by centrifugation at 5,000 g for 10 min at
room temperature and stored at -80°C. Ethical approval
licence number of ILAB Bergen: 119. Experiment no.
0204.
For in vitro inhibition studies, feral Atlantic cod of both
sexes were caught off the West coast of Sweden and placed
in concrete basins provided with recirculating aerated sea-
water at 10 ± 2°C and a salinity of 3.0% and alternative
light/dark photoperiods of 12 hours. Prior to sampling,
the animals were starved and acclimated to these condi-
tions for three weeks. Eight fish were injected i.p. with β-
naphthoflavone (BNF), 50 mg/kg b.w. dissolved in pea-
nut oil (5.0 mg/ml). The fish were placed in a 100 l glass
aquarium provided with aerated seawater (above) and
30% of the water volume was replaced each day. To
eliminate visual stress, the sides of the aquaria were cov-
ered with black plastic sheets. After 3 days exposure, the
fish were sacrificed. Livers were quickly dissected out and
placed in ice-cold homogenization buffer. Livers were
pooled from twenty untreated Atlantic cod and from eight
BNF treated Atlantic cod, respectively. Microsomal frac-
tions were isolated (above) and stored in aliquots at -
80°C. Ethical approval from the Ethical committee of
Göteborg license number (99–2003). The duration of
exposure was decided according to results from previous
time-course studies showing maximal CYP1A protein and
EROD activities in rainbow trout and in the marine vivip-
arous blenny (Zoarces viviparous), 3 days post-injection
with either the prototypical CYP1A inducers BNF or 3-
methylcholanthrene [52-54].
CYP1A- and CYP3A protein blot analyses
Western blot analyses of 40 µg hepatic microsomal pro-
tein were carried out using enhanced chemoluminescence
(ECL), based on the protocol previously described [55]
and PAb raised against rainbow trout CYP1A and CYP3A
[41,55,56]. The intensity of each protein band was deter-
mined by densitometry on scanned fluorograms using
Labview 7.0 from National Instruments (Austin, TX,
USA).
The 2D gel electrophoresis was performed using immobi-
lised pH gradient gels with linear gradient from pH 4 to 7.
The samples were concentrated by acetone precipitation
and pellets dissolved in rehydration buffer (8 M urea, 2 M
thiourea, 20 mM DTT, 4% CHAPS, 0.5% Triton X-100,
0.5% ampholyte 3–10 and <0.02% bromophenolblue) to
a final protein concentration of 20 µg/µl or 80 µg/µl. The
samples were rehydrated overnight followed by isoelectric
focusing for 2.5 h. The rehydration was passive and car-
ried out overnight in an Immobiline Dry Strip reswelling
tray (Amersham Biosciences). First-dimension isoelectric
focusing (IEF) was performed on a Multiphor II unit
(Amersham Biosciences) at 20°C using a MultiDrive XL
power supply (Pharmacia LKB). Settings for IEF were 30
min at 100 V and 3 h at 3500 V for a total of 10,520 Vh.
Amperage and wattage were set to 2 mA and 5 W. The pro-
teins were resolved on 9% continuous acrylamide gel in
Tris:HCl, including sodium dodecyl sulphate polyacryla-
mide using a mini-gel apparatus from BioRad at 200 V for
45 min. Each sample consisted of pooled liver micro-
somes from eight to nine fish from each treatment group.
Gels loaded with 25 µg microsomal protein were initially
stained with 0.1 % (w/v) Coomassie brilliant blue, and
then destained, followed by silver staining. The latter was
performed according to Heukeshoven and Dernick [57].
Stained gels were scanned and analyzed using the
PDQUEST 7.1 software (BioRad). Gels loaded with 100
µg microsomal proteins were electrotransferred toComparative Hepatology 2005, 4:2 http://www.comparative-hepatology.com/content/4/1/2
Page 13 of 15
(page number not for citation purposes)
nitrocellulose membrane and immunoblotted for CYP3A,
as described above.
Catalytic assays
The CYP1A activity was determined as EROD activity,
using resorufin as standard in a SpectraFluor plate reader
according to the protocol provided by Nilsen et al. [58].
The CYP3A catalytic activity was measured as BFCOD
activity, using HFC as standard. The BFC assay was per-
formed based on a published protocol by Miller et al. [59]
and optimized for rainbow trout liver microsomes (T.
Hegelund and M. Celander, unpublished data). The reac-
tion mixture consisted of 200 µM BFC, bovine serum
albumin (1.6 mg/ml), 2 µM NADPH and 10 µl liver
microsomes in a total volume of 200 µl in 0.2 M potas-
sium phosphate buffer pH 7.4 in a 96-multiwell plate
using a VICTOR™ 1420 Multilabel Counter from Wallac
Sverige AB (Upplands Väsby, Sweden).
In vitro inhibition of CYP1A and CYP3A
In vitro inhibition studies were carried out in 96-multiwell
plates using a VICTOR™ 1420 Multilabel Counter. The
IC50  values were determined for nonylphenol, ethy-
nylestradiol, ketoconazole and the ketoconazole:nonyl-
phenol (1:5) mixture on CYP1A and CYP3A activities. The
substances were dissolved in DMSO and diluted with eth-
anol. The final concentrations never exceeded 0.01% (v/v)
DMSO and 0.001% ethanol (v/v). For CYP1A and CYP3A
inhibition studies, pooled liver microsomes from BNF-
treated and from untreated Atlantic cod, respectively, were
used. For comparison, the IC50 values for ketoconazole,
nonylphenol and ethynylestradiol were determined in
cDNA expressed human CYP3A4 baculovirus supersomes
using the CYP3A4 inhibition kit from BD Gentest.
In vitro incubation studies
Pooled liver microsomes from untreated Atlantic cod were
pre-incubated for 10, 30 and 60 min, at room tempera-
ture, with ethynylestradiol and ketoconazole following
CYP3A western blot analysis. The reaction mixture
consisted of microsomes (2.5 or 5.0 mg protein/ml) and
various concentrations of ethynylestradiol (35, 50 and
100  µM) or ketoconazole (0.3 and 1.0 µM) ± 3 µM
NADPH in a total volume of 50 µl in homogenization
buffer, containing 20% (v/v) glycerol. The CYP3A western
blot analysis was performed as described above. Ethy-
nylestradiol and ketoconazole were dissolved in ace-
tonitrile (vehicle) and the final acetonitrile concentration
in the reaction mixture was 0.02% (v/v).
Plasma vitellogenin analysis
Plasma levels of vitellogenin protein were determined
using a non-competitive sandwich ELISA kit and
employing rabbit PAb against Atlantic cod vitellogenin
from Biosense Laboratories AS (Bergen, Norway) [58].
Each plasma sample was diluted (1:20, 1:15,000 and
1:50,000) and 100 µl was analyzed and compared to puri-
fied Atlantic cod vitellogenin protein standards (ranging
between 0.12 and 2,000 ng/ml). The signal was detected
at A492 after 15 min incubation with substrate solution,
using a VICTOR™ 1420 Multilabel Counter.
Plasma sex steroid hormone analyses
Plasma levels of 17β-estradiol and testosterone were
determined using competitive EIA kits from Cayman
Chemical (Ann Arbor, MI, USA). Plasma levels of 11-keto-
testosterone were analyzed using a competitive EIA kit,
from Biosense Laboratories AS (Bergen, Norway). Plasma
from each fish was concentrated (2:1) by extraction once
with six volumes diethyl ether and 50 µl was analyzed and
compared to purified standard substances. The signals
were detected at A405 after 40 min (17β-estradiol), 60 min
(testosterone) or 80 min (11-keto-testosterone) incuba-
tion with substrate solution, using a VICTOR™ 1420 Mul-
tilabel Counter.
Statistics
Data were tested for homogeneity of variances using the
Levene's test. When there was homogeneity of variances
we used a parametric one-way ANOVA, followed by
Scheffé post hoc test. When there was no homogeneity of
variances we used the non-parametric Kruskal-Wallis
ANOVA, followed by the two-tailed Mann-Whitney U test.
No values were log transformed. Data are presented as
means (n = 6–9 fish) accompanied with the standard
deviations (SD). The significance level (α) was set at 0.05.
The statistical analyses were performed using SPSS 11.0
software, from SPSS Sweden AB (Sundbyberg, Sweden).
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